Global Hypercalcemia Treatment Market to Reach $38.3 Billion by 2030
The global market for Hypercalcemia Treatment estimated at US$18.7 Billion in the year 2022, is projected to reach a revised size of US$38.3 Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2022-2030. Bisphosphonates, one of the segments analyzed in the report, is projected to record 9.4% CAGR and reach US$25.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Calcitonin segment is readjusted to a revised 8.7% CAGR for the next 8-year period.The U.S. Market is Estimated at $5.7 Billion, While China is Forecast to Grow at 8.6% CAGR
The Hypercalcemia Treatment market in the U.S. is estimated at US$5.7 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2030 trailing a CAGR of 8.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.7% and 7.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.Select Competitors (Total 38 Featured) -
- AbbVie, Inc.
- Amgen, Inc.
- DiaSorin SpA
- Fujirebio Europe NV
- Kyowa Hakko Kirin Co., Ltd.
- Merck & Co., Inc.
- Novartis AG
- Opko Health, Inc.
- Rockwell Medical
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie, Inc.
- Amgen, Inc.
- DiaSorin SpA
- Fujirebio Europe NV
- Kyowa Hakko Kirin Co., Ltd.
- Merck & Co., Inc.
- Novartis AG
- Opko Health, Inc.
- Rockwell Medical
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 192 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 18.7 Billion |
Forecasted Market Value ( USD | $ 38.3 Billion |
Compound Annual Growth Rate | 9.4% |
Regions Covered | Global |